In obesity-induced muscle atrophy, fibroblast growth factor 19 may promote mitochondrial biogenesis and antioxidant responses via the AMPK/PGC-1α pathway, thereby attenuating the effects of palmitate on mitochondrial dysfunction and oxidative stress [107]. Here, PPARGC1A is linked to obesity disorder.